Latham Advises on Financing for Altaris’ Completed Acquisition of Clarivate’s Life Sciences & Healthcare Business

William Blair downgraded Clarivate Analytics (NASDAQ:CCC) to 'Market Perform' after the company agreed to a $7.75 per share take-private deal, valuing it at $6.1 billion. The stock, trading at $7.62, has risen 16% since the announcement. Analysts see limited upside potential. The deal is expected to close in Q1 2027.

Clarivate (NYSE) sold its Life Sciences & Healthcare business to Altaris for $600M, including $500M in cash, $75M in notes, and $25M deferred. Proceeds will reduce debt. Q2 revenue was $587.3M, down from $621.4M, with a net loss of $268.6M. Clarivate will report Q3 results on Nov 3 and update 2026 guidance.

Wandercraft acquired Ekso Bionics to form a global medical exoskeleton company. Automation Anywhere agreed to buy Boost.ai for conversational AI. Beam Global will acquire ScoutDI for $24M to expand drone tech. Altaris completed a $600M deal for Clarivate's healthcare business.

CLARIVATE PLC (CLVT) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Clarivate Completes Sale of Life Sciences & Healthcare Segment, Advances Strategic Transformation Transaction sharpens strategic focus on leading Academia & Government and Intellectual Property segments Proceeds strengthen balance sheet and enhance financial flexibility London, U

Clarivate (CLVT) completed the $600M sale of its Life Sciences & Healthcare unit to Altaris, narrowing its focus to Academia & Government and Intellectual Property. Proceeds will reduce debt and strengthen its balance sheet. The company plans to update its 2026 guidance on November 3.

Clarivate (NYSE: CLVT) sold its Life Sciences & Healthcare segment to Altaris for $600 million. The company plans to use proceeds to reduce debt and update 2026 guidance. It will focus on Academia & Government and Intellectual Property segments. Q3 2026 results are due November 3, 2026.